Interstitiele longziekten (Interstitial Lung Disease, ILD) Interstitial lung diseases (ILD)
Conditions
Interventions
MRI, PET-MRI, CT scan
Sponsors
Erasmus MC, Universitair Medisch Centrum Rotterdam
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: - Multidisciplinary diagnosis of PF-ILD (progressive fibrotic ILD group including IPF) OR inflammatory ILD (including idiopathic NSIP, ILD related to connective tissue disease or with autoimmune features or chronic hypersensitivity pneumonitis (IGr). - Informed consent - About to start treatment for their ILD. Each patient will be treated as decided in the MDT according to standard clinical practice. PF-ILD and IPF group are usually treated with anti-fibrotic drugs (nintedanib or pirfenidone). The I-ILD group are treated with anti-inflammatory therapy, such as prednisone, mycophenolate mofetil, azathioprine, rituximab. Additional inclusion criteria for subgroup of ILD patients who undergo FDG PET-MRI: PF-ILD group: - Patients of PF-ILD group with sign of disease activity as indicated by PFT and symptoms (dyspnea, exercise capacity, cough) I-ILD group: - Patients of I-ILD group with sign of disease activity as indicated by and symptoms (dyspnea, exercise capacity, cough)
Exclusion criteria
Exclusion criteria: - Contra-indications or inability to undergo MRI (i.e. claustrophobia.) - Current lung infection (according to treating physician) - Respiratory distress at rest despite oxygen - Contra-indication to use gadolinium contrast (severe renal insufficiency, estimated glomerular filtration rate [eGFR]
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Amount of fibrotic and inflammatory lung on chest CT and chest MRI. Response to treatment according to pulmonary function test (PFT) change. | — |
Secondary
| Measure | Time frame |
|---|---|
| - To correlate CT and MRI findings with ILD blood biomarkers and lung function test - To assess whether photon counting chest CT (photon counting CT) is superior to standard CT in terms of resolution, dose reduction and quantification of lung fibrosis | — |
Countries
Netherlands
Contacts
Public ContactP Ciet
Erasmus MC, Universitair Medisch Centrum Rotterdam
Outcome results
None listed